Al Amyloidosis Clinical Trials
9 recruiting trials for Al Amyloidosis. Eligibility criteria explained in plain English.
TrialFinderData lists 9 Al Amyloidosis clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 2 is the largest group at 50% (2 studies); the largest phase groups are Phase 2: 2, Early Phase 1: 1, Phase 1 / Phase 2: 1.
Research is led by Fondazione IRCCS Policlinico San Matteo di Pavia (3), Peking Union Medical College Hospital (2), University Hospital, Angers (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Teclistamab (Tec) (drug, 2 trials), followed by Drug skin tests (investigating hypersensitivity to a biotherapy), Targeted BCMA Autologous CART Cell Injection.
Track Al Amyloidosis trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Evaluation of Skin Tests in Biotherapy Allergies
Biotherapies are biological (extracted from an organism or living tissue) or biotechnological drugs used in the treatment of multiple conditions, such as autoimmune inflammatory...
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research. The purpose of this research...
Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and Treatment
Immunoglobulin light chain (AL) amyloidosis is caused by a typically small, minimally proliferating bone marrow plasma cell clone secreting a patient-unique, unstable,...
Teclistamab in Previously Treated AL Amyloidosis
This is a phase II study in patients with previously treated immunoglobulin light-chain (AL) Amyloidosis to evaluate the efficacy and safety of teclistamab
Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis
This is a phase II study in patients with newly diagnosed Mayo stage IIIB immunoglobulin light-chain (AL) Amyloidosis to evaluate the efficacy and safety of teclistamab
One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS
By detailed sequence analysis and subsequent biophysical characterization of prototypic light chains, this project aims to identify sequence fingerprints in IGLV1-44 light chains...
Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis
Systemic light chain amyloidosis (AL amyloidosis) is the most common type of systemic amyloidosis, with diverse clinical manifestations and difficulties in diagnosis and...
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
The purpose of this study is assess safety, safest dose, and effectiveness of venetoclax in combination with dexamethasone in participants with t(11;14) positive relapsed (comes...
Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
The investigators plan to establish a dedicated network of Italian Hematologic Departments interconnected with the Amyloidosis Research and Treatment Center in Pavia to: 1....
Explore Other Conditions
Frequently Asked Questions
There are currently 9 clinical trials for Al Amyloidosis, with 9 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Al Amyloidosis, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Al Amyloidosis, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.